196
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE “MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY
OF TARGETED AND IMMUNOTARGETED AGENTS IN THE TREATMENT OF
NON-SMALL CELL LUNG CANCER
Rajabo a N.Kh.
Tashken Pha maceu ical Ins i u e, Tashken ci y, Republic o Uzbekis an
e-mail: [email p o ec ed]
h ps://doi.o g/10.5281/zenodo.17332714
Rele ance: non-small cell lung cance (NSCLC) emains one o he leading causes o cance -
ela ed mo bidi y and mo ali y wo ldwide. The in oduc ion o a ge ed he apies (EGFR, ALK,
ROS1 inhibi o s, e c.) and immune checkpoin inhibi o s (PD-1/PD-L1) has ma kedly ans o med
he apeu ic s a egies, shi ing clinical p ac ice owa d a mo e pe sonalized app oach. Despi e no able
ad ances, a sys ema ic e alua ion o accumula ed da a is equi ed o de e mine he op imal
sequencing and combina ion o ea men s, as well as o balance clinical e icacy wi h sa e y
ou comes.
Pu pose o he s udy: o conduc a sys ema ic e iew and me a-analysis o clinical ials
compa ing he e icacy and ole abili y o a ge ed he apies and immuno he apeu ic agen s in
NSCLC.
Ma e ials and me hods: a li e a u e sea ch was pe o med in PubMed, Embase, and he
Coch ane Lib a y o he pe iod 2015–2024. Eligible s udies included andomized clinical ials and
me a-analyses epo ing o e all su i al (OS), p og ession- ee su i al (PFS), objec i e esponse
a e (ORR), and ad e se e en p o iles. Pooled es ima es we e calcula ed using a andom-e ec s
model, and in e s udy he e ogenei y was assessed wi h he I² s a is ic.
Resul s: а o al o 36 s udies, including o e 14,000 pa ien s, we e analyzed. In pa ien s wi h
d i e mu a ions, a ge ed he apies signi ican ly imp o ed PFS (HR = 0.48; 95% CI: 0.41–0.56) and
inc eased ORR up o 65%, ma kedly ou pe o ming chemo he apy. Immuno he apy wi h PD-1/PD-
L1 inhibi o s demons a ed a clinically meaning ul OS bene i in pa ien s wi hou EGFR/ALK
mu a ions and wi h high PD-L1 exp ession (≥50%) (HR = 0.74; 95% CI: 0.66–0.83). Sa e y analysis
e ealed dis inc oxici y p o iles: a ge ed he apies we e associa ed wi h de ma ologic and
gas oin es inal ad e se e en s, whe eas immuno he apy was mo e equen ly linked o immune-
ela ed oxici ies such as pneumoni is, hy oid dys unc ion, and coli is.
Conclusions: This me a-analysis suppo s he p e e en ial use o a ge ed he apies in pa ien s
wi h de ined molecula al e a ions and highligh s he e icacy o immuno he apy in coho s wi h high
PD-L1 exp ession and no d i e mu a ions. Op imal he apeu ic s a egies should be guided by
molecula p o iling and bioma ke assessmen . Combina ion egimens in ol ing a ge ed and
immuno he apeu ic agen s ep esen a p omising di ec ion, wa an ing u he mul icen e ials and
pha macoeconomic e alua ion wi hin na ional heal hca e sys ems.
